Kristen Kloska
Analyst, Cantor Futurals
Replay available
Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Call
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Q1 2025 earnings conference call, held 2025-05-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
AJ Bergman
Chief Financial Officer
Linda Marban
Chief Executive Officer
Ted Tantoff
Analyst, Piper Sandler
Aideen Hasino
Analyst, Ladenburg
Leland Gershall
Analyst, Oppenheimer
Katherine Novak
Analyst, Jones Research
Follow-up Analyst
Analyst
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Capricor Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.697 Good afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics first 00:00:04.697 -- 00:00:09.804 quarter 2025 earnings call. At this time, all participant lines are 00:00:09.804 -- 00:00:14.531 in listen-only mode. Following the presentation, we will conduct a question and answer 00:00:14.531 -- 00:00:19.718 session. If at any time during this call you require immediate assistance, please press 00:00:19.718 -- 00:00:24.864 star zero for the operator. This call is being recorded on Tuesday, May 00:00:24.864 -- 00:00:27.217 13th of 2025. 00:00:27.217 -- 00:00:32.944 I would now like to turn the conference over to our CFO, AJ Bergman, for the forward-looking 00:00:32.944 -- 00:00:36.046 statement. Please go ahead. 00:00:36.829 -- 00:00:40.875 Thank you, and good afternoon, everyone. Before we start, I would like to state that 00:00:40.875 -- 00:00:44.860 we will be making certain forward-looking statements during today's presentation. 00:00:44.860 -- 00:00:48.544 These statements may include statements regarding, among other things, the efficacy, 00:00:48.544 -- 00:00:53.431 safety, and intended utilization of our product candidates, our future R&D plans, including 00:00:53.431 -- 00:00:57.559 our anticipated conduct and timing of preclinical and clinical studies, Our enrollment 00:00:57.559 -- 00:01:02.126 of patients in clinical studies, our plans to present or report additional data, our 00:01:02.126 -- 00:01:06.353 plans regarding regulatory filings, potential regulatory developments involving our product 00:01:06.353 -- 00:01:11.601 candidates, potential regulatory inspections, revenue and reimbursement estimates, projected 00:01:11.601 -- 00:01:15.868 terms of definitive agreements, manufacturing capabilities, ...